Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation.

CONTEXT KLLN is a newly identified gene with unknown function and shares a bidirectional promoter with PTEN. OBJECTIVE The objective of the study was to analyze the relationship between KILLIN (KLLN) expression and prostate cancer and the potential tumor suppressive effect. DESIGN We conducted an in silico analysis to compare KLLN expression in normal prostate and matched primary carcinoma tissues. We subsequently used immunohistochemistry to examine KLLN expression and association with Gleason grade and score in 109 prostatectomy samples. KLLN's tumor-suppressive effect was studied in androgen-dependent and androgen-independent cell models. PATIENTS Patients were diagnosed with peripheral zone prostate carcinomas without metastasis at the time of prostatectomy. Each patient's primary tumor comprised at least 2 tumoral regions with different Gleason grades. RESULTS KLLN expression decreased from normal prostate tissue to primary carcinomas (P < .0001). The loss of epithelial and stromal KLLN expression is associated with poor differentiation and high Gleason scores (P < .0001), consistent with our in vitro observation that KLLN inhibits tumor cell proliferation and invasiveness. KLLN decreases prostate-specific antigen levels and suppresses androgen-mediated cell growth by inhibiting androgen receptor (AR) transcription. As an androgen receptor-regulated target, KLLN also functions as a transcriptional activator, directly promoting the expression of TP53 and TP73, with consequent elevated apoptosis, regardless of AR status. CONCLUSIONS Our observations suggest that KLLN is a transcription factor directly regulating AR, TP53, and TP73 expression, with a role in prostate carcinogenesis. Loss of KLLN associates with high Gleason scores, suggesting that KLLN might be used as a potential prognostic marker for risk management and as a novel therapy target for advanced prostate carcinomas.

[1]  H. Hricak,et al.  Imaging , Diagnosis , Prognosis Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles , 2009 .

[2]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[3]  L. Morel,et al.  Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. , 2002, The Biochemical journal.

[4]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[5]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[6]  Y. Wang,et al.  A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells , 2007, Oncogene.

[7]  C. Eng,et al.  Integrated Analysis Reveals Critical Genomic Regions in Prostate Tumor Microenvironment Associated with Clinicopathologic Phenotypes , 2012, Clinical Cancer Research.

[8]  Desok Kim,et al.  Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.

[9]  W. Gerald,et al.  NF-kappaB regulates androgen receptor expression and prostate cancer growth. , 2009, The American journal of pathology.

[10]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[11]  D. Troyer,et al.  Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. , 2005, Endocrine-related cancer.

[12]  P. C. Supakar,et al.  Functional role of a conformationally flexible homopurine/homopyrimidine domain of the androgen receptor gene promoter interacting with Sp1 and a pyrimidine single strand DNA-binding protein. , 1997, Molecular endocrinology.

[13]  Y. Wang,et al.  Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival , 2008, Oncogene.

[14]  A. Belldegrun,et al.  Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer , 2005, BJU international.

[15]  John Calvin Reed,et al.  Expression of bcl-2 and the progression of human and rodent prostatic cancers. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  Y. Kubota,et al.  Fluorescence in situ hybridization evaluation of c‐myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients , 2000, The Prostate.

[17]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[18]  W. Kaelin,et al.  p73 is a human p53-related protein that can induce apoptosis , 1997, Nature.

[19]  R. Silverman,et al.  Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines , 2010, Human molecular genetics.

[20]  C. Eng,et al.  Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. , 2010, JAMA.

[21]  Peng Liang,et al.  Killin is a p53-regulated nuclear inhibitor of DNA synthesis , 2008, Proceedings of the National Academy of Sciences.

[22]  J. Isaacs,et al.  The biology of hormone refractory prostate cancer. Why does it develop? , 1999, The Urologic clinics of North America.

[23]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[24]  R. Silverman,et al.  Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers , 2011, Oncogene.

[25]  G. Miller,et al.  Molecular genetics and epidemiology of prostate carcinoma. , 1999, Endocrine reviews.

[26]  R. Lanz,et al.  Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.

[27]  J. Eastham,et al.  Androgen receptor mutations in prostate cancer. , 2000, Cancer research.

[28]  J. Moul,et al.  Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. , 1995, The Journal of urology.

[29]  J. Simard,et al.  Science behind total androgen blockade: from gene to combination therapy. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.

[30]  R. Vessella,et al.  Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression* , 2000, The Journal of Biological Chemistry.

[31]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[32]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[33]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[34]  J. Kreisberg,et al.  Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. , 2007, Current cancer drug targets.

[35]  F. Saad,et al.  Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Chawnshang Chang,et al.  Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. , 2004, Molecular endocrinology.

[37]  J. M. Kim,et al.  A novel regulatory element associated with age-dependent expression of the rat androgen receptor gene. , 1993, The Journal of biological chemistry.